more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$127.08 USD

+2.83 (2.28%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $127.12 +0.04 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Sarepta (SRPT) Jumped and We Sold

by Kevin Cook Published on March 12,2018

Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

by Zacks Equity Research Published on March 09,2018

Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

Healthcare Heroes That Aren't Done Yet

by Kevin Cook Published on March 08,2018

Key growth stocks across medical industries tell you the megatrends are in full force for years to come

Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress

by Zacks Equity Research Published on March 02,2018

Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.

Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)

by Zacks Equity Research Published on February 28,2018

Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

SRPTPositive Net Change

BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat

by Zacks Equity Research Published on February 23,2018

BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.

The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

by Zacks Equity Research Published on December 06,2017

The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics

Here's Why Sarepta Stock is Up More Than 70% in 6 Months

by Zacks Equity Research Published on December 05,2017

Sarepta's (SRPT) key product, Exondys 51, and lead pipeline candidate, golodirsen, have put up a good show in the past six months.

5 Top-Ranked Drug Stocks that are Broker Favorites

by Arpita Dutt Published on December 05,2017

With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

4 Biotech Stocks to Better Your Financial Health This Winter

by Zacks Equity Research Published on December 01,2017

The biotech industry shows a solid performance so far this year except for a brief slump in between of late. However, it is a good idea to select stocks from a sector that is fundamentally strong.

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

by Zacks Equity Research Published on November 15,2017

Surging implied volatility makes Sarepta Therapeutics (SRPT) Stock lucrative to the option traders.

SRPTPositive Net Change

BioMarin (BMRN) Q3 Loss Narrows, Profit Guidance Raised

by Zacks Equity Research Published on October 27,2017

BioMarin (BMRN) reported a narrower-than-expected loss in the third quarter of 2017 but missed estimates for sales. The biotech also raised its previously issued adjusted net income guidance for 2017.

Sarepta (SRPT) Q3 Loss Narrows, Exondys 51 Sales View Raised

by Zacks Equity Research Published on October 26,2017

Sarepta (SRPT) beat estimates on both counts in the third quarter of 2017 on strong sales of Exondys 51. Sarepta's pipeline candidate, golodirsen, shows potential.

Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?

by Zacks Equity Research Published on October 24,2017

Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

SRPTPositive Net Change

What's in Store for BioMarin (BMRN) This Earnings Season?

by Zacks Equity Research Published on October 23,2017

BioMarin (BMRN) is likely to see continued momentum in Kuvan sales in Q3. However, slowdown in Federal purchasing orders in Brazil will hurt Naglazyme and Vimizim product revenues.

Catabasis' DMD Candidate Slows Disease Progression, Stock Up

by Zacks Equity Research Published on October 05,2017

Catabasis' (CATB) edasalonexent achieved sustained disease-modifying effects and slowing of progression of duchenne muscular dystrophy in a phase II study.

Here's Why Sarepta Stock is Up More Than 60% So Far in 2017

by Zacks Equity Research Published on September 25,2017

Sarepta (SRPT) shares have been on an uptrend so far this year, fueled by its DMD drug, Exondys 51's strong performance. The settlement of a patent litigation also boosted the stock.

Sarepta's Golodirsen Positive in DMD Study, Shares Soar

by Zacks Equity Research Published on September 07,2017

Sarepta's (SRPT) Duchenne Muscular Dystrophy candidate, Golodirsen, achieved positive muscle biopsy results in first in-human study. Shares surged in response.

Why Is Sarepta (SRPT) Down 9.9% Since the Last Earnings Report?

by Zacks Equity Research Published on August 22,2017

Sarepta (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SRPTPositive Net Change

What You See, and What You Get: The Neurology of Perception

by Kevin Cook Published on August 15,2017

While "the biotech century" cures cancer, it's also tackling dozens of neurological diseases investors should learn about.

BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

by Zacks Equity Research Published on August 03,2017

BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.